![Suneel L. Mahajan](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Suneel L. Mahajan
Geen lopende functies
Loopbaan van Suneel L. Mahajan
Eerdere bekende functies van Suneel L. Mahajan
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Multivir, Inc.
![]() Multivir, Inc. BiotechnologyHealth Technology MultiVir, Inc. is a clinical-stage gene therapy company. It develops a pipeline of novel product candidates for the treatment of multiple oncological indications. The company's gene therapy and oncolytic viral technologies target some of cancer's most fundamental molecular defects. It operates through the following operating segment: business of developing novel cancer treatments. The company product candidates employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors. It currently uses the following three different viral platforms in the development programs: adenovirus, or Ad, herpes simplex virus, or HSV, and vaccinia virus, or VV. MultiVir was founded on November 5, 2009 and is headquartered in Houston, TX. | Directeur/Bestuurslid | 01-02-2015 | - |
Independent Dir/Board Member | 01-02-2015 | - |
Opleiding van Suneel L. Mahajan
B.J. Govt. Medical College & Sassoon General Hospitals | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 2 |
India | 2 |
Operationeel
Director/Board Member | 1 |
Independent Dir/Board Member | 1 |
Doctorate Degree | 1 |
Sectoraal
Health Technology | 2 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Multivir, Inc.
![]() Multivir, Inc. BiotechnologyHealth Technology MultiVir, Inc. is a clinical-stage gene therapy company. It develops a pipeline of novel product candidates for the treatment of multiple oncological indications. The company's gene therapy and oncolytic viral technologies target some of cancer's most fundamental molecular defects. It operates through the following operating segment: business of developing novel cancer treatments. The company product candidates employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors. It currently uses the following three different viral platforms in the development programs: adenovirus, or Ad, herpes simplex virus, or HSV, and vaccinia virus, or VV. MultiVir was founded on November 5, 2009 and is headquartered in Houston, TX. | Health Technology |
- Beurs
- Insiders
- Suneel L. Mahajan
- Ervaring